AU2001294096A1 - Adeno-associated virus-mediated delivery of angiogenic factors - Google Patents
Adeno-associated virus-mediated delivery of angiogenic factorsInfo
- Publication number
- AU2001294096A1 AU2001294096A1 AU2001294096A AU9409601A AU2001294096A1 AU 2001294096 A1 AU2001294096 A1 AU 2001294096A1 AU 2001294096 A AU2001294096 A AU 2001294096A AU 9409601 A AU9409601 A AU 9409601A AU 2001294096 A1 AU2001294096 A1 AU 2001294096A1
- Authority
- AU
- Australia
- Prior art keywords
- delivery
- muscle
- raav
- associated virus
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22605600P | 2000-08-17 | 2000-08-17 | |
US60/226,056 | 2000-08-17 | ||
PCT/IB2001/001902 WO2002014487A2 (fr) | 2000-08-17 | 2001-08-17 | Distribution de facteurs angiogeniques a mediation assuree par virus associe aux adenovirus |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001294096A1 true AU2001294096A1 (en) | 2002-02-25 |
Family
ID=22847367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001294096A Abandoned AU2001294096A1 (en) | 2000-08-17 | 2001-08-17 | Adeno-associated virus-mediated delivery of angiogenic factors |
Country Status (9)
Country | Link |
---|---|
US (2) | US20020111324A1 (fr) |
EP (1) | EP1311699B1 (fr) |
JP (1) | JP2004506658A (fr) |
AT (1) | ATE366319T1 (fr) |
AU (1) | AU2001294096A1 (fr) |
CA (1) | CA2419245A1 (fr) |
DE (1) | DE60129229T2 (fr) |
ES (1) | ES2288993T3 (fr) |
WO (1) | WO2002014487A2 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030157064A1 (en) * | 2001-11-09 | 2003-08-21 | Pascal Neuville | Chimeric promoters for controlling expression in muscle cells |
EP1490107A4 (fr) * | 2002-03-21 | 2005-11-09 | Univ Florida | Modulation de l'angiogenese |
US20030198620A1 (en) * | 2002-04-16 | 2003-10-23 | Keiya Ozawa | Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions |
CN100387723C (zh) * | 2005-12-02 | 2008-05-14 | 浙江大学 | 血管生长素基因重组腺相关病毒载体及制备方法和用途 |
GB0821834D0 (en) * | 2008-11-28 | 2009-01-07 | Iti Scotland Ltd | Calibration and control method |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
CA2966620A1 (fr) | 2014-11-05 | 2016-05-12 | Voyager Therapeutics, Inc. | Polynucleotides codant pour la dopa decarboxylase et destines au traitement de la maladie de parkinson |
SG11201703419UA (en) | 2014-11-14 | 2017-05-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2016112049A1 (fr) * | 2015-01-06 | 2016-07-14 | Cardiovascular Biotherapeutics, Inc. | Traitement angiogénique d'une maladie cardiaque ischémique |
WO2016133848A2 (fr) | 2015-02-16 | 2016-08-25 | Cardiovascular Biotherapeutics, Inc. | Angiogenèse thérapeutique pour le traitement des pathologies érectiles |
WO2017189964A2 (fr) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
EP3448874A4 (fr) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions pour le traitement de maladies |
KR102392236B1 (ko) | 2016-05-18 | 2022-05-03 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
SG11201809643UA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
WO2018204803A1 (fr) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de la maladie de huntington |
CN110913866A (zh) | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
WO2019018342A1 (fr) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Systeme de guide de trajectoire d'appareillage en reseau |
JP7221275B2 (ja) | 2017-08-03 | 2023-02-13 | ボイジャー セラピューティクス インコーポレイテッド | Aavを送達するための組成物および方法 |
WO2019079242A1 (fr) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Traitement de la sclérose latérale amyotrophique (sla) |
JP7502991B2 (ja) | 2017-10-16 | 2024-06-19 | ボイジャー セラピューティクス インコーポレイテッド | 筋萎縮性側索硬化症(als)の治療 |
WO2020069461A1 (fr) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Constructions d'expression de frataxine comprenant des promoteurs modifiés et leurs méthodes d'utilisation |
WO2022026410A2 (fr) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions et méthodes pour le traitement de la maladie de niemann-pick de type c1 |
BR112023001456A2 (pt) | 2020-07-27 | 2023-04-11 | Voyager Therapeutics Inc | Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase |
WO2023091949A2 (fr) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions et méthodes de traitement de troubles neurologiques liés à un déficit en bêta glucosylcéramidase |
WO2023240236A1 (fr) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions et procédés pour le traitement de troubles liés à l'amyotrophie spinale |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0764893A (ja) * | 1993-08-31 | 1995-03-10 | Canon Inc | ネットワーク・システム |
US20030148968A1 (en) * | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
US6004797A (en) * | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
AU1980697A (en) * | 1996-03-04 | 1997-09-22 | Targeted Genetics Corporation | Methods for transducing cells in blood vessels using recombinant AAV vec tors |
US6013780A (en) * | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
NZ505955A (en) * | 1998-02-06 | 2005-04-29 | Collateral Therapeutics Inc | Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF-A, and pharmaceutical use |
AU763049B2 (en) * | 1998-12-28 | 2003-07-10 | Arch Development Corporation | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors |
EP1016726A1 (fr) * | 1998-12-30 | 2000-07-05 | Introgene B.V. | Thérapie génique pour la promotion de l' angiogenèse |
JP2003501092A (ja) * | 1999-06-07 | 2003-01-14 | エドワーズ ライフサイエンシーズ コーポレイション | 標的化新脈管形成 |
US7223406B2 (en) * | 2000-07-21 | 2007-05-29 | The Regents Of The University Of California | Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
-
2001
- 2001-08-17 AU AU2001294096A patent/AU2001294096A1/en not_active Abandoned
- 2001-08-17 EP EP01974582A patent/EP1311699B1/fr not_active Expired - Lifetime
- 2001-08-17 US US09/932,451 patent/US20020111324A1/en not_active Abandoned
- 2001-08-17 AT AT01974582T patent/ATE366319T1/de not_active IP Right Cessation
- 2001-08-17 ES ES01974582T patent/ES2288993T3/es not_active Expired - Lifetime
- 2001-08-17 DE DE60129229T patent/DE60129229T2/de not_active Expired - Lifetime
- 2001-08-17 JP JP2002519615A patent/JP2004506658A/ja active Pending
- 2001-08-17 WO PCT/IB2001/001902 patent/WO2002014487A2/fr active IP Right Grant
- 2001-08-17 CA CA002419245A patent/CA2419245A1/fr not_active Abandoned
-
2006
- 2006-05-26 US US11/441,790 patent/US20070128163A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20070128163A1 (en) | 2007-06-07 |
EP1311699B1 (fr) | 2007-07-04 |
DE60129229D1 (de) | 2007-08-16 |
EP1311699A2 (fr) | 2003-05-21 |
CA2419245A1 (fr) | 2002-02-21 |
DE60129229T2 (de) | 2008-05-08 |
US20020111324A1 (en) | 2002-08-15 |
ES2288993T3 (es) | 2008-02-01 |
JP2004506658A (ja) | 2004-03-04 |
WO2002014487A2 (fr) | 2002-02-21 |
ATE366319T1 (de) | 2007-07-15 |
WO2002014487A3 (fr) | 2003-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001294096A1 (en) | Adeno-associated virus-mediated delivery of angiogenic factors | |
WO2002004623A3 (fr) | Compositions antisens ciblees sur l'arnm specifique aux $g(b)1-adrenocepteurs et procedes d'utilisation correspondants | |
WO2006108718B1 (fr) | Micro arn | |
BE2014C077I2 (fr) | ||
MXPA05006572A (es) | Composiciones y metodos para la administracion mejorada por via mucosa de peptidos fijadores al receptor de y2 y metodos para tratar y prevenir la obesidad. | |
WO1997026337B1 (fr) | Procedes de transmission d'adn a des cellules musculaires a l'aide de virions de virus adeno-associes de recombinaison | |
NO993669D0 (no) | Flersteds avlevering av adenoviral vektor for induksjon av angiogenese | |
IL219528A0 (en) | Vaccine comprising recombinant modified vaccine ankara virus and uses thereof | |
JP2004506658A5 (fr) | ||
WO2002074980A3 (fr) | Muteines du facteur de transcription alpha inductible en hypoxie | |
CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
DK1677833T3 (da) | Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom | |
EA200200533A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ ДОСТАВКОЙ ГЕНОВ in vivo | |
TW200531700A (en) | Uses of melanocortin-4 receptor (MC4R) agonist peptides administered by continuous infusion | |
WO1998050079A3 (fr) | Techniques et compositions destinees au traitement d'une insuffisance cardiaque et du remodelage ventriculaire par apport in vivo de transgenes angiogeniques | |
EP1149917A3 (fr) | Vecteurs derivés du virus Hépatitis B pour la thérapie gènique | |
NZ529915A (en) | Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186 | |
WO2002064746A3 (fr) | Systeme de ciblage transcriptionnel et transductionnel combine pour insertion de genes | |
MX2022002132A (es) | Administracion de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular. | |
BR0012556A (pt) | Genes e vacinas de ehrlichia canis | |
DK1556494T3 (da) | Bicistronisk vektor, der koder en VEGF og en FGF, samt anvendelse deraf | |
Retroviruses | 845. Properties of Sindbis Virus Vectors Produced with a Chimeric Split Helper System | |
MY119381A (en) | Recombinant mva virus, and the use thereof | |
MY134484A (en) | Recombinant mva virus, and the use thereof |